Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal

     Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic
    Lymphocytic Leukemia Published in The New England Journal of Medicine

PR Newswire

SUNNYVALE, Calif., June 19, 2013

SUNNYVALE, Calif., June 19, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the
"Company") (Nasdaq: PCYC) today announced that The New England Journal of
Medicine (NEJM) published results online of a Phase 1b/2 study evaluating the
investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib in
patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL). Ibrutinib was shown to be safe and effective in
patients with relapsed/refractory CLL or SLL, even in patients who were at
high-risk due to factors such as deletion of part of chromosome 17 (del 17p).

Results of a separate study examining the safety and efficacy of ibrutinib
monotherapy for the treatment of relapsed/refractory mantle cell lymphoma
(MCL) has also been published online in NEJM today. Pharmacyclics sponsored
both studies and is jointly developing ibrutinib with Janssen Research &
Development, LLC.

The open-label study reported on 85 patients with relapsed/refractory CLL or
SLL. The majority of patients had advanced disease and had previously
undergone treatment with several rounds of therapies before enrollment in the
study. Approximately one-third of patients enrolled in the study presented
with a malignancy carrying del 17p. Patients with del17p typically respond
poorly to chemoimmunotherapy, which is the current standard treatment for CLL.

"Patients with CLL and SLL have a great need for new, well tolerated and
effective therapies," said lead author John C. Byrd, M.D., Director, Division
of Hematology, D Warren Brown Professor of Leukemia Research, The Ohio State
University Comprehensive Cancer Center. "These data are particularly exciting,
as they demonstrate benefit for high risk CLL and SLL patients, with efficacy
consistent across doses and continuing durable remissions lasting in excess of
two years in the great majority of patients treated." 

Study participants were enrolled selected to receive either ibrutinib 420 mg
(n=51) or 840 mg (n=34) as a once-daily, oral monotherapy. Both doses were
associated with overall response rates of 71 percent. Del17p patients had an
overall response rate of 68 percent. Two patients in the 420 mg dose arm had
complete responses and 34 patients had partial responses. Across all relapsed
or refractory patients, including the high risk patients, the estimated
progression-free survival at 26 months was 75 percent. An additional 20
percent of patients treated with the 420 mg dose and 15 percent of patients
taking the 840 mg dose achieved a partial response accompanied by
lymphocytosis, an elevated blood lymphocyte count.

The majority of adverse events (AEs) observed in the study were considered to
be Grade 1 or 2 in severity, including diarrhea, infections and fatigue. A
total of six patients taking ibrutinib experienced an AE leading them to
discontinue treatment with the drug. Severe AEs observed during the treatment
period include pneumonia and dehydration (12 percent and six percent,
respectively), as well anemia, neutropenia and thrombocytopenia (six percent,
15 percent and six percent, respectively). Grade 3-4 hematological toxicities
were not common.

Data from this study were presented at the annual meeting of the American
Society of Hematology in December 2012.

Study Design
The Phase 1b/2, open-label, multicenter study was designed to determine the
safety, efficacy, pharmacokinetics and pharmacodynamics of ibrutinib in
patients with relapsed or refractory CLL. The primary objective of the study
was to determine the safety of the two fixed-dose regimens of ibrutinib,
assessed by evaluating the frequency and severity of AEs. Secondary efficacy
endpoints included: overall response rate, progression-free survival and an
exploratory endpoint of overall survival.

The study enrolled patients with a confirmed diagnosis of relapsed or
refractory CLL or small lymphocytic lymphoma (a disease that mirrors the
symptoms and progression of CLL) at eight sites in the U.S. Patients who
participated in the study had a median of four prior therapies and 65 percent
of the patients had advanced disease. Twenty-eight CLL patients had del17p, a
genetic mutation associated with a poor prognosis.

About CLL
CLL is a slow-growing blood cancer that starts in the white blood cells
(lymphocytes), specifically the B-cells. CLL is the most common adult
leukemia. Approximately 16,000 patients in the US are diagnosed each year with
CLL. The prevalence of CLL is approximately 113,000 in the US. It is a chronic
disease of the elderly with an average survival of about five years after
diagnosis. Patients commonly receive multiple lines of treatment over the
course of their disease.

In CLL the genetic mutation del17p occurs when the short arm of chromosome 17
is missing. Del17p is associated with abnormalities of a key tumor suppressor
gene, TP53, which results in poor response to chemoimmunotherapy and worse
treatment outcomes. It occurs in about seven percent of treatment naïve CLL
patients, with approximately 20-40 percent of relapsed/refractory patients
harboring the mutation. 

About ibrutinib
Ibrutinib was designed to specifically target and selectively inhibit an
enzyme called BTK. BTK is a key mediator of at least three critical B-cell
pro-survival mechanisms occurring in parallel – regulating B-cell apoptosis,
cell adhesion, and lymphocyte migration and homing. Through these multiple
actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus
allowing access to a microenvironment necessary for survival.

The effectiveness of ibrutinib alone or in combination with other treatments
is being studied in several B-cell malignancies, including chronic lymphocytic
leukemia/small lymphocytic lymphoma, relapsed/refractory mantle cell lymphoma,
diffuse large B-cell lymphoma, follicular lymphoma and multiple myeloma. The
clinical development program currently includes30 clinical trials,
includingsix Phase 3 trials. Details about the complete ibrutinib clinical
program is posted on clinicaltrials.gov. Janssen Biotech, Inc. and
Pharmacyclics entered a collaboration and license agreement in December 2011
to co-develop and co-commercialize ibrutinib.

About Pharmacyclics
Pharmacyclics^® is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative small-molecule drugs for the
treatment of cancer and immune mediated diseases. Our mission and goal is to
build a viable biopharmaceutical company that designs, develops and
commercializes novel therapies intended to improve quality of life, increase
duration of life and resolve serious unmet medical healthcare needs; and to
identify promising product candidates based on scientific development
expertise, develop our products in a rapid, cost-efficient manner and pursue
commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has two product candidates in clinical development
and several preclinical molecules in lead optimization. The Company is
committed to high standards of ethics, scientific rigor, and operational
efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ
under the symbol PCYC. To learn more about how Pharmacyclics advances science
to improve human healthcare visit us at http://www.pharmacyclics.com. 

NOTE: This announcement may contain forward-looking statements made in
reliance upon the safe harbor provisions of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended, including statements, among others, relating to our future capital
requirements and the sufficiency of our current assets to meet these
requirements, our future results of operations, our expectations for and
timing of ongoing or future clinical trials and regulatory approvals for any
of our product candidates, and our plans, objectives, expectations and
intentions. Because these statements apply to future events, they are subject
to risks and uncertainties. When used in this announcement, the words
"anticipate", "believe", "estimate", "expect", "expectation", "should",
"would", "project", "plan", "predict", "intend" and similar expressions are
intended to identify such forward-looking statements. These forward-looking
statements are based on information currently available to us and are subject
to a number of risks, uncertainties and other factors that could cause our
actual results, performance or achievements to differ materially from those
projected in, or implied by, these forward-looking statements. Factors that
may cause such a difference include, without limitation, our need for
substantial additional financing and the availability and terms of any such
financing, the safety and/or efficacy results of clinical trials of our
product candidates, our failure to obtain regulatory approvals or comply with
ongoing governmental regulation, our ability to commercialize, manufacture and
achieve market acceptance of any of our product candidates, for which we rely
heavily on collaboration with third parties, and our ability to protect and
enforce our intellectual property rights and to operate without infringing
upon the proprietary rights of third parties. Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we
cannot guarantee future results, performance or achievements and no assurance
can be given that the actual results will be consistent with these
forward-looking statements. For more information about the risks and
uncertainties that may affect our results, please see the Risk Factors section
of our filings with the Securities and Exchange Commission, including our
annual report on Form 10-K and quarterly reports on Form 10-Q. We do not
intend to update any of the forward-looking statements after the date of this
announcement to conform these statements to actual results, to changes in
management's expectations or otherwise, except as may be required by law.

Contact:
Ramses Erdtmann
Vice President of Investor Relations and Corporate Communications
Phone: 408-215-3325

U.S. Medical Information, Pharmacyclics:
855-Ibrutinib [(855) 427-8846]

SOURCE Pharmacyclics, Inc.

Website: http://www.pharmacyclics.com
 
Press spacebar to pause and continue. Press esc to stop.